目的 探究弥可保在治疗糖尿病缺血性视神经病变的临床疗效及安全性. 方法 选取2012年5月-2014年5月期间到该院进行临床治疗的106例糖尿病缺血性视神经病变患者作为研究对象,以随机法平均分成研究组与对照组. 研究组患者给予弥可保联合维生素B1进行治疗;对于对照组患者给予常规的腺苷钴胺片、维生素B1和维生素B12进行临床治疗,然后对比两组患者的临床治疗效果. 结果 临床随诊3个月后,研究组的总有效率高达96.23%,而对照组的为83.02%,研究组的总有效率明显高于对照组,差异有统计学意义(P<0.05);对于不良反应的发生率,研究组患者为0,而对照组患者为5.66%. 研究组明显低于对照组,差异有统计学意义(P<0.05). 结论 弥可保在糖尿病缺血性视神经病变的临床治疗上,具有很高的临床疗效,且不良反应的发生率更低,安全性好,值得在临床上推广应用.%Objective To explore the clinical efficacy and safety of Methycobal in treatment of diabetic ischemic optic neuropathy. Methods 106 cases of diabetic patients with ischemic optic neuropathy treated in our hospital from May 2014 to May 2012 were randomly divided into study group and control group. The patients were randomly divided into study group and control group. Patients in the study group was given Methycobal and vitamin B1 treatment; for in control group were treated with conventional cobamamide tablets, vitamin B1 and vitamin B12 for clinical treatment and compared two groups of patients with clinical therapeutic effect. Results the total effective rate of the study group was three, while the control group was 83.02%, and the difference was significant (P<0.05). The incidence of adverse reactions was 0, while the control group was 5.66%, while the control group was 96.23%. The study group was significantly lower than the control group, the difference was significant, with statistical significance (P<0.05). Conclusion methycobal on diabetic ischemic re-garded clinical treatment of neuropathy, with a very high clinical efficacy and lower incidence of adverse reactions, good safety, it is worth in clinical application.
展开▼
